Huabo Biopharm
Hangzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An oncology-focused biotech developing novel antibody therapeutics for cancer treatment.
Oncology
Technology Platform
An integrated antibody discovery and engineering platform for generating high-affinity monoclonal and bispecific antibodies against oncology targets.
Opportunities
Large and growing global oncology market with continuous demand for more effective and targeted treatments, especially in China.
Risk Factors
High risk of clinical failure and difficulty in achieving meaningful differentiation in a crowded therapeutic landscape with similar mechanisms.
Competitive Landscape
Enters a crowded oncology antibody market with intense competition from both multinational corporations and a growing number of well-funded Chinese biotechs.